BREO ELLIPTA
Total Payments
$47,258
Transactions
2,741
Doctors
1,879
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $405.68 | 27 | 26 |
| 2021 | $92.36 | 5 | 5 |
| 2020 | $27,510 | 1,740 | 1,321 |
| 2019 | $761.87 | 78 | 53 |
| 2018 | $723.18 | 64 | 36 |
| 2017 | $17,765 | 827 | 458 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $45,553 | 2,733 | 96.4% |
| Consulting Fee | $1,700 | 7 | 3.6% |
| Education | $5.17 | 1 | 0.0% |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $47,258
Product Information
- Type Drug
- Total Payments $47,258
- Total Doctors 1,879
- Transactions 2,741
About BREO ELLIPTA
BREO ELLIPTA is a drug associated with $47,258 in payments to 1,879 healthcare providers, recorded across 2,741 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2022. In 2022, $405.68 was paid across 27 transactions to 26 doctors.
The most common payment nature for BREO ELLIPTA is "Food and Beverage" ($45,553, 96.4% of total).